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Abstract
Background: Demographic change concurrent with medical progress leads to an increasing number of elderly
patients in intensive care units (ICUs). Antibacterial treatment is an important, often life-saving, aspect of intensive
care but burdened by the associated antimicrobial resistance risk. Elderly patients are simultaneously at greater risk
of infections and may be more restrictively treated because, generally, treatment intensity declines with age. We
therefore described utilization of antibacterials in ICU patients older and younger than 80 years and examined
differences in the intensity of antibacterial therapy between both groups.
Methods: We analysed 17,464 valid admissions from the electronic patient data management system of our
surgical ICU from April 2006 – October 2013. Antibacterial treatment rates were defined as days of treatment
(exposed patient days) relative to patient days of ICU stay and calculated for old and young patients. Rates
were compared in zero-inflated Poisson regression models adjusted for patients’ sex, mean SAPS II- and TISS-
scores, and calendar years yielding adjusted rate ratios (aRRs). Rate ratios exceeding 1 represent higher rates
in old patients reflecting greater treatment intensity in old compared to younger patients.
Results: Observed antibacterial treatment rates were lower in patients 80 years and older compared to younger patients
(30.97 and 39.73 exposed patient days per 100 patient days in the ICU, respectively). No difference in treatment intensity,
however, was found from zero-inflated Poisson regression models permitting more adequate consideration of patient
days with low treatment probability: for all antibacterials the adjusted rate ratio (aRR) was 1.02 (95%CI: 0.98–
1.07). Treatment intensities were higher in elderly patients for penicillins (aRR 1.37 (95%CI: 1.26–1.48)), cephalosporins
(aRR 1.20 (95%CI: 1.09–1.31)), carbapenems (aRR 1.35 (95%CI: 1.20–1.50)), fluoroquinolones (aRR 1.17 (95%CI: 1.05–1.30),
and imidazoles (aRR 1.34 (95%CI: 1.23–1.46)).
Conclusions: Elderly patients were generally less likely to be treated with antibacterials. This observation, however, did
not persist in patients with comparable treatment probability. In these, antibacterial treatment intensity did
not differ between younger and older ICU patients, for some antibacterial classes treatment intensity was
even higher in the latter. Patient-level covariates are instrumental for a nuanced evaluation of age-effects in
antibacterial treatment in the ICU.
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Background
Severe infectious complications such as sepsis are common
and increasing in critically ill patients in intensive care units
(ICUs) [1, 2]. Concurrently, the rising prevalence of multi-
resistant organisms in ICUs forces clinicians to use
antibacterial combinations and agents of last resort for
management of such infections, thereby further fostering
antimicrobial resistance development [3–5]. Antibacterial
therapy thus places intensive care physicians in a worsening
dilemma of providing adequate therapy for the individual
while considering not only the good of the single patient but
of the whole ICU [6]. This conflict especially applies to older
patients who are on the one hand at greater risk for devel-
oping infections [7] and on the other hand may only experi-
ence limited benefit from aggressive therapy, especially at
the end of life [6, 8]. Elderly patients may consequently re-
ceive a disproportionately large share of antibacterials and
thus are a group of interest upon which to focus antibacter-
ial utilization improvement activities, such as antibiotic
stewardship programs. By contrast, general treatment inten-
sity in ICUs declines with advancing age [9–13], although it
is acknowledged that age alone should not be decisive for
this [7, 9, 14]. These conflicting treatment tendencies make
it unclear if current utilization of antibacterials in elderly
ICU patients differs from that of younger ones. This ques-
tion is of increasing importance given that the proportion of
elderly patients requiring complex care is predicted to rise
due to the demographic change [11, 15–18]. To the best of
our knowledge, however, no studies have yet investigated
differences in antibacterial therapy in older compared to
younger ICU patients. Moreover, previous antibacterial drug
utilization studies in ICUs have focused on total antibacter-
ial consumption or impacts of antibiotic stewardship pro-
grams, while data quantifying antibacterial therapy based on
individual patient data are scarce.
In this study we therefore compared antibacterial ther-
apy in adult ICU patients above and below 80 years, a
cut-off applied previously for studies in this setting [8–
10, 13, 15, 16, 18]. We hypothesized that in our ICU eld-
erly compared to younger patients more often require
antibacterial treatment. In addition to all antibacterials
we also separately assessed different antibacterial drug
classes to detect potential differences in local therapy
patterns between the two age groups, and to reveal dif-
ferential utilization of antibacterials in our ICU associ-
ated with high resistance risk. Because in our ICU both
patients with urgent and no need for antibacterial treat-
ment are treated concomitantly, we accounted for this
situation with adequate analytical methods.
Methods
Data source and cohort definition
The data used for this study were extracted from the
patient data management system (IntelliVue Clinical
Information Portfolio, Philips, Eindhoven, Netherlands)
of the Department of Anesthesiology and Surgical Inten-
sive Care Medicine at University Hospital Mannheim,
Germany. The same data source has been used previ-
ously [19]. The available data consisted of anonymized
electronic medical records on patients treated in our 26-
bed surgical ICU from April 2006 to October 2013.
Consistent with our aim of including the whole ICU-
population during the study period in our analyses, the
cohort was defined as all valid admissions of patients
aged 18 years or older with known sex and age and a
minimum stay of 10 min. Follow-up started on ICU ad-
mission or the beginning of electronic records, which-
ever was earlier, and continued until the earliest of
discharge, death in the ICU, or end of available data.
Though patients could be admitted more than once to
the ICU during the study period, we refer to individual
admissions as patients. Age was categorized into < 80
and ≥ 80 years.
The referring department of each admission was ex-
tracted. We additionally analysed microbiological test re-
sults of blood cultures and bronchoalveolar lavages from
all patients in the ICU between 26/03/2007 and 31/12/
2013 to establish time trends in bacteria isolated on our
ward. In excluding other samples, such as routine ad-
mission swabs, we focused on results with relevance for
antibacterial treatment. Furthermore, the Charlson co-
morbidity score [20] was determined from ICD-10 codes
from administrative hospital discharge data [21] for all
patients with indicator for treatment in the ICU during
the study period. However, as there was no individual
linkage to the electronic medical records of the ICU, this
information served for comparative description only and
could not be included in the analyses on antibacterial
treatment.
Antibacterial exposure and treatment measures
Entries of antibacterials in the electronic medical record
during follow-up were identified and categorized into anti-
bacterial drug classes according to the WHO Anatomical
Therapeutic Chemical Classification System (ATC). The
following classes were administered: tetracyclines
(J01AA12), penicillins (J01CA01, J01CA04, J01CA10,
J01CA12, J01CF04, J01CF05), cephalosporins (J01DB04,
J01 DC02, J01DD01, J01DD02, J01DD04, J01DE01), carba-
penems (J01DH02, J01DH03, J01DH04, J01DH51),
macrolides (J01FA01, J01FA09), lincosamides (J01FF01),
aminoglycosides (J01GB01, J01GB03, J01GB06), fluoro-
quinolones (J01MA01, J01MA02, J01MA12, J01MA14),
glycopeptides (J01XA01), imidazoles (J01XD01), and
oxazolidinones (J01XX08). In addition, some other anti-
bacterials were administered which do not belong to one
of the aforementioned classes (colistin (J01XB01), fosfo-
mycin (J01XX01), daptomycin (J01XX09), and rifampicin
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(J04AB02)). The 368 records for these were only consid-
ered in analyses of all antibacterials.
There are several possibilities to measure antibacterial
exposure and consumption, all of which have their ad-
vantages and disadvantages [22–24]. In addition to de-
fining patients with at least one record of any
antibacterial during their ICU stay as exposed patients,
we used three antibacterial utilization measures (Add-
itional file 1: Figure S1): (1) Antibacterial prescriptions
represented individual entries of antibacterials in our
electronic patient record. These comprised separate
doses, e.g., infusions or flow rates of syringe pumps. A
patient could therefore have multiple entries of the same
antibacterial on a given day depending on how the daily
dose was split up. Consequently, ranking and compar-
ability of prescriptions between classes is limited. We
therefore also analysed (2) antibacterial therapy days,
defined as days in which antibacterial prescriptions of
one or more particular classes were recorded. If a patient
received antibacterials of two or more different drug
classes in one calendar day, two or more therapy days
were counted. Thus, this measure reflects both combin-
ation and change of antibacterial classes and mainly
served for illustration of time trends in treatment com-
plexity. Finally, we defined (3) exposed patient days as
calendar days in which at least one antibacterial agent,
irrespective of the class, was administered, i.e., at least
one antibacterial prescription was recorded. This meas-
ure, relative to days of patient stay, allowed calculation
of antibacterial exposure rates. A calendar day in which
a patient stayed at least 1 min in the ICU was defined as
a patient day. Consequently, a patient could have more
antibacterial prescriptions than therapy days and more
therapy days than exposed patient days.
These measures were determined for all patients and
all antibacterials. In addition, all antibacterials excluding
the macrolide erythromycin due to its nearly exclusive
off-label use as a prokinetic agent in our ICU were
quantified accordingly. Furthermore, exposed patient
days were counted for all antibacterial drug classes sep-
arately. Macrolides were analysed both with and without
erythromycin, with clarithromycin being the only other
macrolide administered to our cohort. In the category
‘all antibiotics’ and ‘all antibiotics except erythromycin’
the abovementioned other antibacterials not belonging
to one of the drug classes were also included.
Cofactors
The respective age group was the main covariate of
interest. In addition, we included the patient’s sex, the
year of treatment, severity of the acute illness as
expressed by the Simplified Acute Physiology Score II
(SAPS II) [25], as well as the Therapeutic Intervention
Scoring System (TISS) [26] assessing intensity of patient
care as adjusting factors in the analysis. As usual in Ger-
man ICUs, a simplified TISS-score is recorded in our
electronic patient record which contains the ten most
intensive therapeutic measures (‘TISS-10’). SAPS II-
scores were re-calculated by subtracting the points con-
tributed to the overall SAPS II-score by the age category
to allow comparability of actual severity of acute illness
between the age groups [10, 12, 13, 15]. For every pa-
tient the means of available daily SAPS II- and TISS-10-
scores of a given admission were calculated. Missing
scores were set to 0, i.e., for SAPS II parameters normal
values and for TISS-10 no interventions were assumed.
Strategies for addressing potential confounding
The statistical models were adjusted for the above-
mentioned cofactors to minimize differences in disease
severity or other characteristics impacting infection risk
between the age groups that are potentially associated
with antibacterial treatment (potential confounding).
These cofactors mainly reflected acute disease severity
and intensity of therapeutic measures received by the
patient. The SAPS II-score, however, additionally consid-
ered metastatic malignant tumours, haematological ma-
lignancy and AIDS and thus also served as a rough
surrogate for significant chronic comorbidity. Our
models did not include the treatment indication, i.e., the
type of infection and causative bacterial agent. They
were not adjusted for individual chronic comorbid con-
ditions affecting infection risk, such as diabetes, and im-
munocompromised states, e.g., due to drug therapy. The
models also contained no information on body weight,
smoking, or alcohol intake.
Statistical analysis
We examined differences between medians (due to
skewed distributions) and frequencies for basic cohort
parameters for all patients and both age groups with
Mann-Whitney-U-tests and Pearson’s Chi2-tests respect-
ively. We used standard Poisson regression to calculate
the rates of exposed patient days (numerator of rate) per
100 patient days (denominator of rate) with 95% confi-
dence intervals (95%CI) for all patients and for each age
group separately. Furthermore, we calculated rate ratios
for patients aged ≥80 compared to < 80 years of age
yielding exposed patient days for patients ≥80 per 100
exposed patient days for patients < 80 by using zero-
inflated Poisson regression. We chose the zero-inflation
model since most patients of our cohort did not receive
any antibacterial treatment and so had zero exposed pa-
tient days, i.e., there were excess zeros in the data.
The rates and rate ratios comprise the whole study
period and were calculated for all antibacterial drug clas-
ses, all drug classes except erythromycin and for each drug
class separately. The rate ratios were both unadjusted and
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adjusted for the patients’ sex, mean SAPS II- and TISS-
score, and year of treatment. As a sensitivity analysis the
subgroup of patients with more than 48 h of ICU treat-
ment was described and analysed in the same way, with
erythromycin excluded from the exposure definition. The
analyses were conducted with SAS 9.4 (SAS Institute, Inc.,
Cary, NC).
Results
Of 17,464 valid admissions to our ICU between April
2006 and October 2013 the majority were male (57.1%)
and 2640 (15.1%) belonged to the age group of 80 and
above (Table 1). Mean age was 63.8 ± 16.3 years and the
median length of stay 0.9 days (interquartile range (IQR):
0.8–2.6), with a higher median of 2.8 (IQR: 0.8–8.3) in
the 1448 (8.3%) non-survivors. Slightly more than one
third had at least one valid SAPS II- and TISS-10-score
(36.3%). The median of the means was 20.1 (IQR: 13.3–
28.9) for SAPS II without age-points and 9.7 (IQR: 5.0–
12.5) for TISS-10. Patients with a SAPS II- and TISS-
score contributed to 72.2% of total patient days. Most
admissions of the cohort and in young patients were
neurosurgical, whereas older patients were most often
transferred from orthopaedics (Additional file 1: Table
S1). For all ICU patients the median Charlson score was
2, (IQR: 0–3) with higher scores in old compared to
young patients (median 2, IQR: 1–4 vs. median 2, IQR:
0–3, p < 0.0001).
About one third of patients were treated with antibac-
terials during their ICU stay (Table 1). Of these, an even
larger proportion than in the full cohort was male
(64.6%) and younger than 80 years (87.5%). Mean age
was thus slightly lower compared to the whole cohort
(62.4 ± 16.2 years), whereas length of stay (median 2.2
days (IQR: 0.9–8.7) was greater. While in the full cohort
the proportion of females in patients aged 80 or above
was larger than that of males, only about half of the eld-
erly patients treated with antibacterials were female.
More than 190,000 antibacterial prescriptions were re-
corded for all patients during the study period (ca. 140,
000 when excluding erythromycin), for which penicillins
accounted for the most (Table 2). This is likely due to
predominant administration of the penicillin class mem-
ber piperacillin with syringe pumps, for which frequent
records are created. In contrast, the largest number of
exposed patients received cephalosporins, while most ex-
posed patient days were observed for macrolides (pre-
dominantly erythromycin).
In patients 80 years and older the largest proportion was
exposed to cephalosporins, imidazoles and penicillins, in
the younger group the largest fraction of patients was
exposed to cephalosporins, macrolides and imidazoles.
Table 1 Basic characteristics of the ICU cohort and patients treated with antibacterials
Characteristic All patients < 80 years ≥80 years p-value*
Full cohort
Number of patients 17,464 14,824 (84.9%) 2640 (15.1%)
Patient days 76,424 67,480 8944
Length of stay (median, IQR (days)) 0.9 (0.8–2.6) 0.9 (0.8–2.7) 0.9 (0.8–2.0) 0.0004
Female patients 7498 (42.9%) 5875 (39.6%) 1623 (61.5%) < 0.0001
ICU mortality rate 1448 (8.3%) 1136 (7.7%) 312 (11.8%) < 0.0001
SAPS II (median of means, IQR)a 20.1 (13.3–28.9) 19.9 (13.0–28.6) 22.0 (15.0–30.0) < 0.0001
TISS-10 (median of means, IQR) 9.7 (5.0–12.5) 10.0 (5.7–12.6) 7.5 (5.0–11.1) < 0.0001
Patients treated with antibacterials
Number of patients 5785 (33.1%b) 5060 (34.1%c) 725 (27.5%c) < 0.0001
Patient days 44,936 40,831 4105
Length of stay (median, IQR (days)) 2.2 (0.9–8.7) 2.3 (0.9–9.1) 2.0 (0.9–5.7) 0.0142
Female patients 2047 (35.4%) 1689 (33.4%) 358 (49.4%) < 0.0001
ICU mortality rate 869 (15.0%) 726 (14.4%) 143 (19.7%) 0.0002
SAPS II (median of means, IQR)a 24.6 (17.5–32.7) 24.4 (17.3–33.0) 25.8 (18.5–31.5) 0.4291
TISS-10 (median of means, IQR) 10.7 (7.5–14.1) 10.8 (7.8–14.4) 9.0 (5.0–12.1) < 0.0001
Exposed patient days 29,578 26,808 2770
Number of Antibacterial prescriptions 190,689 172,963 17,726
Therapy days 52,342 47,630 4712
*from Chi2-Test for proportions and Mann-Whitney-U-Test for continuous variables (two-sided with significance level of p < 0.05)
aSAPS II calculated without age points
bPercent of full cohort
cPercent of age group
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Antibacterial prescriptions, however, were mostly re-
corded for penicillins and macrolides in both age groups.
Penicillins, followed by imidazoles and macrolides,
accounted for the most exposed patient days in elderly pa-
tients, whereas younger patients were by far most often
exposed to macrolides, cephalosporins and carbapenems.
Overall, in the cohort there were 38.70 (95%CI: 38.26–
39.15) exposed patient days per 100 patient days (global
rate), and 32.81 (95%CI: 32.41–33.22) exposed patient
days per 100 patient days when excluding erythromycin
(Table 3). The rate for patients aged < 80 years was
higher (39.73 (95%CI: 39.25–40.21)) than the rate for
older patients (30.97 (95%CI: 29.84–32.15)). These ob-
served rates with confidence intervals from an un-
adjusted standard Poisson model reflect the actual status
quo of antibacterial exposure in our ICU for all patients
Table 2 Antibacterial treatment measures for both age groups
Drug class Patients < 80 years Patients≥ 80 years
Exposed
patients
Prescriptions Exposed patient
days
Exposed
patients
Prescriptions Exposed patient
days
All antibacterials 5060 (100%a) 172,963 (100%b) 26,808 (100%a) 725 (100%a) 17,726 (100%b) 2770 (100%a)
All antibacterials except erythromycin 4673 (92.4%) 125,855 (72.8%) 22,597 (84.3%) 680 (93.8%) 14,567 (82.2%) 2477 (89.4%)
Tetracyclines 93 (1.8%) 1098 (0.6%) 631 (2.4%) 6 (0.8%) 67 (0.4%) 37 (1.3%)
Penicillins 1349 (26.7%) 63,655 (36.8%) 5640 (21.0%) 211 (29.1%) 8741 (49.3%) 806 (29.1%)
Cephalosporines 1711 (33.8%) 10,901 (6.3%) 6208 (23.2%) 248 (34.2%) 1041 (5.9%) 689 (24.9%)
Carbapenems 890 (17.6%) 14,973 (8.7%) 5787 (21.6%) 81 (11.2%) 961 (5.4%) 389 (14.0%)
Macrolides 1574 (31.1%) 47,311 (27.4%) 10,366 (38.7%) 168 (23.2%) 3183 (18.0%) 734 (26.5%)
Clarithromycin 34 (0.7%) 203 (0.1%) 124 (0.5%) 7 (1.0%) 24 (0.1%) 17 (0.6%)
Lincosamides 219 (4.3%) 966 (0.6%) 465 (1.7%) 40 (5.5%) 194 (1.1%) 95 (3.4%)
Aminoglycosides 85 (1.7%) 689 (0.4%) 361 (1.3%) 6 (0.8%) 26 (0.1%) 16 (0.6%)
Fluoroquinolones 1474 (29.1%) 13,954 (8.1%) 4950 (18.5%) 198 (27.3%) 1447 (8.2%) 556 (20.1%)
Glycopeptides 88 (1.7%) 473 (0.3%) 297 (1.1%) 9 (1.2%) 28 (0.2%) 17 (0.6%)
Imidazoles 1483 (29.3%) 12,601 (7.3%) 5297 (19.8%) 230 (31.7%) 1762 (9.9%) 768 (27.7%)
Oxazolidinones 493 (9.7%) 5771 (3.3%) 3163 (11.8%) 36 (5.0%) 251 (1.4%) 147 (5.3%)
aSum of proportions of antibacterial classes exceeds 100% as patients could have been exposed to more than one class
bSum of prescriptions is slightly lower than 100% as some rarely used antibacterials were not analysed as separate classes, see methods section for details
Table 3 Rates and rate ratios with 95%CIs for antibacterial therapy by drug class
Drug class Observed rate
(whole ICU cohort) a
Observed rate patients
aged < 80 yearsa
Observed rate patients
aged≥ 80 yearsa
Unadjusted rate
ratio ≥ 80 vs. < 80b
Adjusted rate
ratio≥ 80 vs. < 80c
All Antibacterials 38.70 (38.26–39.15) 39.73 (39.25–40.21) 30.97 (29.84–32.15) 0.99 (0.94–1.03) 1.02 (0.98–1.07)
All antibacterials except erythromycin 32.81 (32.41–33.22) 33.49 (33.05–33.93) 27.69 (26.63–28.81) 1.05 (1.00–1.10) 1.07 (1.02–1.12)
Tetracyclines 0.87 (0.81–0.94) 0.94 (0.86–1.01) 0.41 (0.30–0.57) 2.26 (1.59–3.22) 1.87 (1.25–2.81)
Penicillins 8.43 (8.23–8.64) 8.36 (8.14–8.58) 9.01 (8.41–9.66) 1.41 (1.29–1.53) 1.37 (1.26–1.48)
Cephalosporins 9.02 (8.81–9.24) 9.20 (8.97–9.43) 7.70 (7.15–8.30) 1.22 (1.11–1.34) 1.20 (1.09–1.31)
Carbapenems 8.08 (7.88–8.28) 8.58 (8.36–8.80) 4.32 (3.91–4.77) 1.29 (1.15–1.44) 1.35 (1.20–1.50)
Macrolides 14.52 (14.26–14.80) 15.36 (15.07–15.66) 8.21 (7.63–9.82) 0.96 (0.88–1.04) 0.97 (0.90–1.06)
Clarithromycin 0.18 (0.16–0.22) 0.18 (0.15–0.22) 0.19 (0.12–0.31) 1.17 (0.64–2.14) 1.02 (0.51–2.04)
Lincosamides 0.73 (0.67–0.80) 0.69 (0.63–0.75) 1.06 (0.87–1.30) 1.41 (1.08–1.83) 1.40 (1.05–1.86)
Aminoglycosides 0.49 (0.45–0.55) 0.53 (0.48–0.59) 0.18 (0.11–0.29) 1.12 (0.61–2.04) 1.11 (0.61–2.02)
Fluoroquinolones 7.20 (7.02–7.40) 7.34 (7.13–7.54) 6.22 (5.72–6.76) 1.24 (1.12–1.37) 1.17 (1.05–1.30)
Glycopeptides 0.41 (0.37–0.46) 0.44 (0.39–0.49) 0.19 (0.12–0.31) 2.16 (1.14–4.10) 1.69 (0.90–3.20)
Imidazoles 7.94 (7.74–8.14) 7.85 (7.64–8.06) 8.59 (8.00–9.22) 1.36 (1.25–1.48) 1.34 (1.23–1.46)
Oxazolidinones 4.33 (4.19–4.48) 4.69 (4.53–4.85) 1.64 (1.40–1.93) 1.22 (1.02–1.47) 1.30 (1.08–1.56)
aExposed patient days per 100 patient days
bZero-inflated Poisson-regression
cZero-inflated Poisson-regression adjusted for mean SAPS II- and TISS-scores, sex, and year of treatment
Beier et al. BMC Health Services Research          (2019) 19:367 Page 5 of 9
and both age groups. In contrast, the rate ratios of the
zero-inflated Poisson-model can be interpreted as the in-
tensity of treatment in patients above 80 compared to
those below 80 years for those patients who were likely
to be treated. The exposure rate ratio (RR) adjusted for
sex, mean SAPS II- and TISS-scores, and year of treat-
ment for all antibacterials was 1.02 (95%CI: 0.98–1.07)
indicating a comparable treatment intensity in both age
groups. For all antibacterials except erythromycin (ad-
justed RR 1.07 (95%CI: 1.02–1.12) and all individual
antibacterial drug classes except for macrolides, amino-
glycosides and glycopeptides adjusted exposure rate ra-
tios reflected significantly higher rates in older patients
or a greater treatment intensity compared to patients
younger than 80 years. An analysis restricted to patients
with more than 48 h of stay in our ICU yielded highly
robust results (Additional file 1: Tables S3 and S4). In
this group, only 59 or 1.2% had neither SAPS II- nor
TISS-scores.
For all antibacterials there was no overall time trend in
treatment intensity and no difference in comparative treat-
ment intensity for the age groups over time as both the year
and interaction of year and age did not reach statistical sig-
nificance in the zero-inflated Poisson model. This is con-
gruent with positive microbiological test results from blood
cultures and bronchioalveolar lavage. Their number in-
creased steadily during the study period, but the most com-
mon infectious agents were consistently identified as
Staphylococci, E. coli, and Candida albicans (Additional file
1: Table S2). Treatment intensity was slightly lower,
however, for female compared to male patients (adjusted
RR 0.96 (95%CI: 0.93–0.98)).
While the proportion of patients aged ≥80 years
remained stable during the study period at around 15%
in our ICU (Fig. 1), in both age groups the number of
exposed patient days increased relative to 100 patient
days. There was an even greater increase in antibacterial
treatment days relative to patient stay, reflecting increas-
ing complexity of treatment. Except for the years 2007
and 2008 the same trends were observed for both age
groups, although the rates for patients < 80 years were
consistently higher.
Discussion
During the study period about one in three admissions
to our ICU received antibacterials and one in eight was
80 years or older. Antibacterial prescriptions, antibacter-
ial therapy days and exposure rate to antibacterials were
all lower in older compared to younger patients. How-
ever, alongside high-risk patients our ICU admits pa-
tients for routine post-surgical surveillance with low
infection risk who are predominantly elderly and con-
tribute numerous person days free of antibacterial ex-
posure. We therefore accounted for the baseline
probability of antibacterial treatment with zero inflated
Poisson regression. The resulting adjusted exposure rate
ratios indicated no difference for all antibacterials, i.e.,
global treatment intensity was comparable, for most
antibacterial classes there was even evidence for higher
treatment intensity in elderly patients.
Fig. 1 Time trends of exposed patient days and treatment days by age group, and percentage of elderly patients in the ICU cohort. Proportion of
patients aged ≥80 years from a German 26-bed surgical ICU based on 17,464 admissions from April 2006 to October 2013. Antibacterial treatment
trends are reflected by the fraction of therapy days (sum of different classes of which antibacterial agents were administered in a day) per 100
patient days and exposed patient days (days of ICU stay in which at least one antibacterial agent irrespective of the class was administered) per
100 patient days
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Based on exposure rates, the most often used classes in
our ICU during the study period were macrolides, cepha-
losporins, penicillins and carbapenems. Ignoring macro-
lides - predominantly erythromycin used off-label as
prokinetic agent - our findings are consistent with other
studies reporting β-lactams as most often used, with peni-
cillins in a French [27] and a German ICU [28], and high-
est consumption of cephalosporins followed by penicillins,
carbapenems, and fluoroquinolones in Swedish ICUs,
[29]. In a Spanish multi-centre study also β-lactams as a
whole, carbapenems, and fluoroquinolones were most
widely used [30].
In contrast to our findings, previous studies on mech-
anical ventilation have revealed less aggressive therapy
and less ICU admissions for the elderly even after ad-
justment for disease severity [9, 10, 12, 13].
The discrepancy between observed and adjusted com-
parative antibacterial exposure can be reconciled as both
results representing different aspects of the antibacterial
treatment process, with the former reflecting treatment
decision and the latter treatment implementation. Our
results thus suggest there is no differential treatment of
elderly patients once the treatment decision is made.
The decision for treatment initiation, however, appears
to be dependent on age or factors strongly associated
with age. This includes the association of age with both
a low treatment need, particularly in patients admitted
for short-term routine post-surgical recovery, as well as
with a decision against treatment. The greater difference
between observed exposure rates in old and young pa-
tients regardless of treatment duration compared to
rates from those with > 48 h of treatment supports that
the first scenario was probably true for a significant pro-
portion of old patients. Unfortunately, information on
life-sustaining treatment limitations was not at our dis-
posal to distinguish both scenarios definitively. We ex-
pect that younger and older patients with a priori
explicit strong wish not to be aggressively treated are
unlikely to be admitted to our surgical ICU. However,
information on treatment preferences is often not
sought before ICU admission [31], but, as varying by
centre [32], may concern a significant proportion of eld-
erly [33], potentially leading to a lower treatment prob-
ability for elderly in our study. Indeed, given their higher
mortality in our ICU, for elderly probably more often
the question arose whether life-prolonging therapy was
still useful and in the patient’s interest [6, 8].
The lower treatment intensity in female patients may re-
flect sex-specific differences in infectious disease incidence
but also differences in treatment implementation due to
other causes. While some studies report contradictory re-
sults on differences in general treatment intensity in ICUs
[34–37], Nachtigall et al. [37] did not find sex-based differ-
ences in antibacterial therapy in a sepsis cohort.
To our knowledge no previous study has explicitly fo-
cused on age-dependent differences in antibacterial ther-
apy in ICU patients. Instead of aggregated data often
used for antibacterial drug utilization studies we ana-
lysed patient-level data. We could thereby account for
potential confounding in the age-group comparison by
considering individual disease severity using the SAPS
II-score together with therapeutic intensity reflected by
TISS-10. Our findings of an at least comparable antibac-
terial treatment intensity in older ICU patients were
confirmed in analyses restricted to patients with > 48 h
of ICU treatment, who can be considered as high-risk
for infection. This supports use of the zero-inflated Pois-
son model for all patients which facilitates a comparison
to ICU-wide descriptive antibacterial utilization data.
Moreover, this suggests general utility of this method for
situations when a two-stage treatment process is likely
but restriction of analyses to a subgroup with high treat-
ment probability is not desirable or possible.
Our results provide a snapshot of antibacterial
utilization in the ICU setting, treatment indication, how-
ever, was unknown. A distinction between ICU-imported
and ICU-acquired infections was also not possible and the
fraction of empirical antibacterial treatments is unknown.
However, as the vast majority (83.3%) of patients treated
for > 48 h received antibacterials within their first 48 h, a
significant proportion of infections present on admission
or soon thereafter is likely. Moreover, as our results reflect
a single surgical ICU in Germany their generalizability is
limited. Infectious disease incidence and infectious agents
expectedly vary in other intensive care settings, such as
neurological or cardiac surgery ICUs, and the difference
between age groups may vary accordingly. In addition,
antibacterial prescription practice can already differ be-
tween ICUs of the same country [24, 29]. Conclusions be-
yond German ICUs should be drawn even more
cautiously since health care systems and services vary sub-
stantially across Western Europe and North America [38].
This variation also affects the ICU admission process [39].
Triage decisions lead to selective admission of elderly ex-
pected to benefit from admission who are likely more
often treated than elderly refused ICU admission. It is un-
known if our local triage was more or less restrictive than
elsewhere and information on refused patients was not
available. Thus, interpretation of our results requires
consideration of the fact that they are only based on
patients admitted according to local decision practice.
Nevertheless, in addition to the cohort characteristics,
the information on referring departments and micro-
biological isolates from our ICU provides some con-
text for external comparisons.
While a binary age classification facilitated a simple in-
terpretation of the exposure rate ratios, in further studies
a greater number of age subgroups should be investigated,
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e.g., as previously defined as young-old (65–74 years), old-
old (75–84 years), and very-old (> 84 years) [40]. More-
over, future investigations should include information on
potential confounders such as antibacterial treatment indi-
cation and individual comorbidity, particularly diabetes
and malignant diseases, immunosuppressant medication,
as well as body weight, smoking and alcohol intake. A
possible time-dependency of the treatment difference in
the age groups based on length of stay should be consid-
ered. Future studies should also distinguish ICU-imported
and ICU-acquired infections.
Conclusion
In our surgical ICU elderly patients were less often
treated with antibacterials than patients younger than
80 years. In those likely to be treated, however, intensity
was at least similar in older compared to younger pa-
tients. These findings support differentiation between
age as a factor for treatment decision and treatment im-
plementation. This requires confirmation in studies from
other surgical and non-surgical ICUs, which ideally
should include data on treatment indication.
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